Greenwich Lifesciences FY25 net loss widens 11% to $19.36 million

• Greenwich Lifesciences posted a net loss of $19.4 million in 2025, widening from $17.4 million in 2024.
• R&D expenses rose 11% to $17.22 million, driven by higher clinical expenses for the Phase III Flamingo-01 trial.
• General and administrative costs increased 3% to $2.23 million; cash climbed to $6.18 million at Dec. 31, 2025.
• Net cash used in operating activities widened to $9.91 million; financing cash inflows increased to $12 million on ATM stock sales.
• Flamingo-01 is being expanded into Europe, with plans to open up to 150 sites globally to evaluate GLSI-100 in HER2/neu-positive patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-026651), on June 01, 2026, and is solely responsible for the information contained therein.